Olanoff L S, Walle T, Walle U K, Cowart T D, Gaffney T E
Clin Pharmacol Ther. 1984 Jun;35(6):755-61. doi: 10.1038/clpt.1984.107.
Our objective was to determine the kinetics of (+)- and (-)-propranolol after intravenous doses of racemic drug. Five normal subjects received 0.1 mg/kg of a pseudoracemate of propranolol that consisted of deuterium-labeled (+)-propranolol and unlabeled (-)-propranolol. Plasma concentrations of (+)- and (-)-propranolol as measured by gas chromatography-mass spectrometry demonstrated enantiomeric differences in systemic clearance (Cls) [(+)-propranolol, 1.21 +/- 0.15 l/min; (-)-propranolol, 1.03 +/- 0.12 l/min; P less than 0.01] and apparent volume of distribution (Vd) [(+)-propranolol, 4.82 +/- 0.34 l/kg; (-)-propranolol, 4.08 +/- 0.33 l/kg; P less than 0.001], but no difference in distribution or elimination t1/2s (t1/2 beta 3.5 hr). The higher Cls of (+)-propranolol suggests stereoselective hepatic elimination. The higher apparent Vd of (+)-propranolol is mainly related to its lower plasma binding [(+)-propranolol, 20.3 +/- 0.8% unbound; (-)-propranolol, 17.6 +/- 0.7% unbound; P less than 0.001]. There was no stereoselective uptake by red blood cells. These findings demonstrate that multiple stereoselective mechanisms are involved in the disposition of propranolol and determine the access of the drug to active sites.
我们的目的是确定静脉注射消旋普萘洛尔后(+)-和(-)-普萘洛尔的动力学。五名正常受试者接受了0.1mg/kg的普萘洛尔假消旋体,该假消旋体由氘标记的(+)-普萘洛尔和未标记的(-)-普萘洛尔组成。通过气相色谱-质谱法测定的(+)-和(-)-普萘洛尔的血浆浓度显示,在全身清除率(Cls)方面存在对映体差异[(+)-普萘洛尔,1.21±0.15l/min;(-)-普萘洛尔,1.03±0.12l/min;P<0.01]以及表观分布容积(Vd)方面存在差异[(+)-普萘洛尔,4.82±0.34l/kg;(-)-普萘洛尔,4.08±0.33l/kg;P<0.001],但在分布或消除半衰期(t1/2β为3.5小时)方面无差异。(+)-普萘洛尔较高的Cls表明存在立体选择性肝清除。(+)-普萘洛尔较高的表观Vd主要与其较低的血浆蛋白结合率有关[(+)-普萘洛尔,20.3±0.8%未结合;(-)-普萘洛尔,17.6±0.7%未结合;P<0.001]。红细胞不存在立体选择性摄取。这些发现表明,多种立体选择性机制参与了普萘洛尔的处置,并决定了药物进入活性位点的情况。